CN Patent

CN105377267A — 依帕列净的治疗用途

Assigned to Boehringer Ingelheim International GmbH · Expires 2016-03-02 · 10y expired

What this patent protects

本发明涉及用于在肾损伤或慢性肾病(CKD)患者中治疗和/或预防代谢障碍，例如1型或2型糖尿病或前驱糖尿病的具体SGLT-2抑制剂。

USPTO Abstract

本发明涉及用于在肾损伤或慢性肾病(CKD)患者中治疗和/或预防代谢障碍，例如1型或2型糖尿病或前驱糖尿病的具体SGLT-2抑制剂。

Drugs covered by this patent

Patent Metadata

Patent number
CN105377267A
Jurisdiction
CN
Classification
—
Expires
2016-03-02
Drug substance claim
No
Drug product claim
No
Assignee
Boehringer Ingelheim International GmbH
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.